MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
BRC Blood Theme and BRC/NHS Translational Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
Br J Haematol. 2019 May;185(3):436-449. doi: 10.1111/bjh.15817. Epub 2019 Mar 5.
Congenital dyserythropoietic anaemia type I (CDA-I) is one of a heterogeneous group of inherited anaemias characterised by ineffective erythropoiesis. CDA-I is caused by bi-allelic mutations in either CDAN1 or C15orf41 and, to date, 56 causative mutations have been documented. The diagnostic pathway is reviewed and the utility of genetic testing in reducing the time taken to reach an accurate molecular diagnosis and avoiding bone marrow aspiration, where possible, is described. The management of CDA-I patients is discussed, highlighting both general and specific measures which impact on disease progression. The use of interferon alpha and careful management of iron overload are reviewed and suggest the most favourable outcomes are achieved when CDA-I patients are managed with a holistic and multidisciplinary approach. Finally, the current understanding of the molecular and cellular pathogenesis of CDA-I is presented, highlighting critical questions likely to lead to improved therapy for this disease.
先天性红细胞生成不良性贫血 I 型(CDA-I)是一组异质性遗传性贫血中的一种,其特征为无效红细胞生成。CDA-I 由 CDAN1 或 C15orf41 的双等位基因突变引起,迄今为止,已有 56 个致病突变被记录。本文回顾了诊断途径,并描述了基因检测在缩短获得准确分子诊断所需时间以及在可能的情况下避免骨髓穿刺方面的作用。讨论了 CDA-I 患者的治疗方法,重点介绍了影响疾病进展的一般和具体措施。本文回顾了干扰素 α 的使用和铁过载的精心管理,并表明当 CDA-I 患者采用整体和多学科方法进行管理时,可获得最佳结果。最后,本文介绍了对 CDA-I 的分子和细胞发病机制的当前理解,强调了可能导致该疾病治疗改善的关键问题。